For this study, researchers analyzed U.S. federal research data in which people were asked about their GLP-1 prescriptions. Results showed that among people without diabetes, GLP-1 drug use rose ...

The rising use of glucagon-like peptide-1 (GLP ... of drug that mimics the glucagon-like peptide-1 hormone. It stimulates insulin secretion and reduces appetite, helping to control blood sugar and ...

The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas of ...

However, it is important to note that the study's cross-sectional design means these findings are correlational, not causal; the data do not show that these factors cause interest in GLP-1 use.

Novo Nordisk's GLP-1 receptor ... alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use for the versatile drug class. The small, 48-subject study ...

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 agonist drugs form part of their treatment, new research being presented at ...

Share on Pinterest Research is looking for ways to minimize muscle loss from GLP-1 drugs taken to treat ... said that “this study was helpful to show that some muscle can occur with significant ...

(CNN) — The use of ... a new study finds, even though there’s little information on the drugs’ safety and effectiveness for the condition. The family of medications called GLP-1 receptor ...

GLP-1 drugs have helped ... on proper medication use, resistance training, and adequate protein intake. Body composition was measured at the start of the study, at three months, and again at ...